Prospera Financial Services Inc reduced its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Get a rating) by 13.0% in the first quarter, Holdings Channel.com reports. The institutional investor held 30,804 shares of the biopharmaceutical company after selling 4,586 shares during the quarter. Prospera Financial Services Inc’s holdings in Catalyst Pharmaceuticals were worth $255,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also bought and sold shares of the company. Point72 Hong Kong Ltd increased its stake in Catalyst Pharmaceuticals by 84.3% in the 4th quarter. Point72 Hong Kong Ltd now owns 5,932 shares of the biopharmaceutical company worth $40,000 after buying 2,713 additional shares last quarter. Koss Olinger Consulting LLC acquired a new position in Catalyst Pharmaceuticals in Q4 for a value of approximately $71,000. Nkcfo LLC bought a new position in Catalyst Pharmaceuticals in Q1 worth approximately $99,000. Zurcher Kantonalbank Zurcher Kantonalbank increased its stake in Catalyst Pharmaceuticals to 99.8% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,535 shares of the biopharmaceutical company worth $137,000 after buying 8,258 additional shares last quarter. Finally, Teacher Retirement System of Texas increased its stake in Catalyst Pharmaceuticals by 17.4% in the 4th quarter. Teacher Retirement System of Texas now owns 18,642 shares of the biopharmaceutical company worth $126,000 after buying 2,757 additional shares last quarter. Hedge funds and other institutional investors hold 64.28% of the company’s shares.
A Wall Street analyst gives his opinion
Separately, StockNews.com cut Catalyst Pharmaceuticals shares from a “strong buy” rating to a “buy” rating in a Wednesday, July 13 research note. Five investment analysts rated the stock with a buy rating. Based on data from MarketBeat.com, the company currently has a consensus Buy rating and a consensus target price of $10.92.
Performance of Catalyst Pharmaceuticals shares
Shares of Stock Catalyst Pharmaceuticals opened at $10.58 on Wednesday. Catalyst Pharmaceuticals, Inc. has a 52-week low of $4.81 and a 52-week high of $10.72. The stock has a market capitalization of $1.09 billion, a price-earnings ratio of 25.19 and a beta of 1.44. The company has a fifty-day moving average of $7.77 and a 200-day moving average of $7.52.
Pharmaceutical Catalyst (NASDAQ:CPRX – Get a rating) last reported quarterly earnings data on Tuesday, May 10. The biopharmaceutical company reported earnings per share (EPS) of $0.12 for the quarter, missing consensus analyst estimates of $0.14 per ($0.02). Catalyst Pharmaceuticals had a net margin of 29.31% and a return on equity of 23.95%. The company posted revenue of $43.09 million in the quarter, compared to $43.17 million expected by analysts. During the same period last year, the company posted EPS of $0.09. On average, stock research analysts expect Catalyst Pharmaceuticals, Inc. to post earnings per share of 0.67 for the current fiscal year.
Insider Buying and Selling at Catalyst Pharmaceuticals
In other Catalyst Pharmaceuticals news, an insider Gary Ingenito sold 6,152 shares in a trade on Wednesday, June 22. The shares were sold at an average price of $6.61, for a total transaction of $40,664.72. Following the completion of the sale, the insider now owns 22,053 shares of the company, valued at approximately $145,770.33. The sale was disclosed in a filing with the Securities & Exchange Commission, available at this link. 12.80% of the shares are currently held by company insiders.
Catalyst Pharmaceuticals Company Profile
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, is focused on developing and commercializing therapies for people with chronic debilitating, neuromuscular and neurological rare diseases in the United States. It offers Firdapse, an amifampridine phosphate tablet for the treatment of patients with Lambert-Eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.
Get news and reviews for Catalyst Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com’s free daily email newsletter.